Experienced in Pure Red Cell Aplasia

Zimin M. Sun

No. 17 Lujiang Road, 
Hefei, CN 
Experienced in Pure Red Cell Aplasia
No. 17 Lujiang Road, 
Hefei, CN 
OverviewLocationsClinical Research

Overview

Zimin Sun practices in Hefei, China. Sun is rated as an Experienced expert by MediFind in the treatment of Pure Red Cell Aplasia. Their top areas of expertise are Graft Versus Host Disease (GvHD), Leukemia, ABO Incompatibility, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 113 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Pure Red Cell Aplasia.

Locations

No. 17 Lujiang Road, Hefei, 230001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
View 1 Less Clinical Trial

113 Total Publications

Alternative-Donor Transplants in Adults ≤ 55 Years Old With Haematological Cancers: Young Versus Older Related HLA-Haplotype-Mismatched Donor Versus Unrelated Umbilical Cord Blood.
Alternative-Donor Transplants in Adults ≤ 55 Years Old With Haematological Cancers: Young Versus Older Related HLA-Haplotype-Mismatched Donor Versus Unrelated Umbilical Cord Blood.
Journal: Clinical transplantation
Published: June 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sun's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile